Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer

Laryngoscope

Volumn 109, Issue 3, 1999, Pages 389-395

  O'Malley Jr , Bert W ^a,c   Li, Daqing ^a   Buckner, Alyson ^a   Duan, Ling ^a   Woo, Savio L C ^b   Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 1496   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOLYSIS; GENE THERAPY; GENE TRANSFER; HYPOTHESIS; MOUSE; MOUTH CANCER; NONHUMAN; PLAQUE FORMING CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH; VIRUS GENE;

EID: 0033038295     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199903000-00009     Document Type: Article

References (22)

1. Fearon ER, Pardoll DM, Itaya R, Golumbek P, Levitsky H, Simons J. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
2. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 1976;193:1007-1008.
3. Kuribayashi K, Gillis S, Kern DE, et al. Murine NK cell cultures: effects of interleukin-2 and Interferon on cell growth and cytotoxic reactivity. J Immunol 1981;126:2321-2327.
4. Henney CS, Kern DE, Gillis S. Cytotoxic responses: the regulatory influence of interleukin-2. Transplant Proc 1982;14:565-569.
5. Henney CS, Kuribayashi K, Kern DE, et al. Interleukin-2 augments natural killer cell activity. Nature 1985;291:335-338.
6. Rosenberg SA, Lotze M, Maul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
7. West WH, Touer KW, Yanelli JR. Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
8. Rook AH, Masur H, Lane HC, et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983;72:398-403.
9. Pardoll DM. Cancer vaccines. Immunol Today 1993;14(6):310-316.
10. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-1224.
11. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-716.
12. De Stefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G. .Treatement of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J Immunother 1996;19(2):125-133.
13. Chen S-H, Li Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995;92:2577-2581.
14. O'Malley BW Jr, Cope KA, Chen S-H, Li D, Schwartz MR, Woo SLC. Combination gene therapy for oral cancer in a murine model. Cancer Res 1996;56:1737-1741.
15. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997;89(1):21-39.
16. Boucher RC, Knowles MR, Johnson LG, Olsen JC. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. Hum Gene Ther 1994;5:615-639.
17. Rosenfeld MA, Yoshimurea K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992;68:143-155.
18. Welsh MJ, Smith AE, Zabner J, et al. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. Hum Gen Ther 1994;5:209-219.
19. O'Malley BW Jr, Sewell DA, Li D, et al. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 1997;11(6):667-673.
20. O'Malley BW Jr, Chen S-H, Schwartz MR, Woo SLC. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995;55:1080-1085.
21. Fu KK, Rayner PA, Lam KN. Modification of the effects of continuous low-dose radiation by concurrent chemotherapy infusion. Int Radiat Oncol Biol Phys 1984;10:1473-1477.
22. Xiaomei J, Nguyen D, Zhang W-W, Kyritsis AP, Roth JA. Cell cycle arrest and inhibition of tumor cell proliferation by the p16 gene mediated by an adenovirus vector. Cancer Res 1995;55:3250-3253.